Comparative Pharmacology
Head-to-head clinical analysis: DEPO ESTRADIOL versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO ESTRADIOL versus THEELIN.
DEPO-ESTRADIOL vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol is an estrogen hormone that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting effects such as proliferation of endometrial tissue, regulation of gonadotropin secretion (negative feedback on FSH and LH), and maintenance of secondary sexual characteristics.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
1 to 5 mg intramuscularly every 3 to 4 weeks for estrogen replacement therapy.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
The terminal elimination half-life of estradiol after intramuscular injection of Depo-Estradiol is approximately 5-9 days, reflecting slow release from the depot and prolonged systemic exposure.
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
Estradiol is extensively metabolized in the liver, with conjugated metabolites (glucuronides and sulfates) primarily excreted in urine (about 90%) and feces (about 10%). Less than 5% is excreted unchanged.
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category D/X
Category C
Estrogen
Estrogen